At a glance
ClinicalIndex Comparison RecordPhase 2Active· 41 enrolled
Drug / intervention
Ibrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma
In Brief
A Phase 2 clinical trial evaluating Ibrutinib and Laboratory Biomarker Analysis for Grade 3a Follicular Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 41 participants across 13 sites in 3 countries.
Detailed Summary
This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGrade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Follicular Lymphoma
CountriesCanada, Singapore, United States
Collaborators--
Timeline
Phase 2Active
201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2013
First PostedMay 2013
Primary CompletionJun 2016
TodayJul 2026
Study CompletionMar 2027
First PostedMay 8, 2013
Enrollment StartApr 2, 2013
Primary CompletionJun 3, 2016
Study CompletionMar 19, 2027
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.2 years ago
Interventions
Ibrutinibdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies